US SB419 | 2019-2020 | 116th Congress
Status
Spectrum: Partisan Bill (Democrat 1-0)
Status: Introduced on February 7 2019 - 25% progression, died in committee
Action: 2019-02-07 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on February 7 2019 - 25% progression, died in committee
Action: 2019-02-07 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Requires the Food and Drug Administration (FDA) to revoke approval for an opioid drug for every new opioid drug approved. (Opioids are drugs with effects similar to opium, such as certain pain medications.) In determining the drug for which to revoke approval, the FDA must prioritize revoking approval for drugs that are not abuse deterrent and consider the public health impact of drugs on the market.
Title
Protecting Americans from Dangerous Opioids Act
Sponsors
Sen. Joe Manchin [D-WV] |
History
Date | Chamber | Action |
---|---|---|
2019-02-07 | Senate | Read twice and referred to the Committee on Health, Education, Labor, and Pensions. |
Subjects
Drug safety, medical device, and laboratory regulation
Drug trafficking and controlled substances
Health
Prescription drugs
Drug trafficking and controlled substances
Health
Prescription drugs
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/116th-congress/senate-bill/419/all-info |
Text | https://www.congress.gov/116/bills/s419/BILLS-116s419is.pdf |